Fierce Biotech1 min read
saveNovartis shareholder calls for board overhaul following costly deal setbacks: Reuters
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
comments(0)
5-min edit window · permanent after that